ART 5803
Alternative Names: ART-5803Latest Information Update: 18 Sep 2023
At a glance
- Originator Arialys Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anti-N-methyl-D-aspartate-receptor-encephalitis
Most Recent Events
- 12 Sep 2023 Astellas Pharma acquires ART 5803 from Arialys Therapeutics
- 12 Sep 2023 Arialys Therapeutics announces intention to submit IND for clinical trial in anti N-methyl-D-aspartate receptor encephalitis in 2024
- 12 Sep 2023 ART 5803 receives Orphan Drug status for Anti-N-methyl-D-aspartate receptor encephalitis in USA